Tafamidis Meglumine

Pfizer's first-quarter revenues, at $13.7 billion, declined 8% from last year's first quarter. Pfizer is raising the bar for its sweeping cost-savings drive yet again, this time cranking up the total target to $7.7 billion through 2027.Of that total, $4.5 billion in net cost savings will be realized by the end of this year from an ongoing cost-realignment program, the company said in its first-quarter earnings update. In addition to previously disclosed cuts, the company is plotting an additional $1.2 billion in cost cuts largely tied to selling, informational and administrative functions. The company plans to achieve these savings thanks to the use of digital tools such as automation and AI, as well as simplification of its business processes, chief financial officer David Denton explained on a Tuesday conference call.Meanwhile, the R&D organization isn't avoiding the axe. Pfizer anticipates making $500 million in R&D cuts by the end of 2026, with the "savings to be reinvested to the pipeline," the company said in the update.The $1.7 billion in total new cuts come on top of a multibillion-dollar reorganization plan first unveiled in 2023. In October of that year, Pfizer laid out its intention to start an "enterprise-wide cost realignment program" that would chop $3.5 billion in annual expenses. The company added $500 million to the target in late 2023, then another $1.5 billion in May 2024 and $500 million in December 2024.It’s a long-running mission supporting Pfizer’s goal of returning to pre-pandemic operating margins and driving operating efficiencies, Denton noted on the Tuesday call.The reorganization isn't strictly about downsizing, though. As of the first quarter of 2025, the company had reinvested $2.2 billion into internal R&D projects, according to the Tuesday update. New chief scientific officer Chris Boshoff, M.D., Ph.D., has “moved both thoughtfully and quickly” in reshaping the R&D organization, CEO Albert Bourla, Ph.D., said on the conference call.As for Pfizer's financial performance during the quarter, the drugmaker generated global sales of $13.7 billion, an 8% decline from the same period last year. The drop was largely attributed to a 75% sales decline in sales of COVID-19 antiviral Paxlovid. On the flip side, COVID vaccine Comirnaty is doing better than its antiviral counterpart, delivering a 62% revenue boost versus the first quarter of 2024. Outside of Pfizer's COVID products, heart disease franchise Vyndaqel grew sales 33% through “continuing uptake” in patient diagnoses. Other quarterly growth drivers included urothelial cancer antibody-drug conjugate (ADC) Padcev, migraine med Nurtec and lung cancer therapy Lorbrena.Pfizer is sticking with its previously announced full-year revenue guidance of $61 billion to $64 billion, which as of now does not include potential impacts from future tariffs and policy changes, the company noted. However, to help “navigate this fluid environment,” the company is deploying a cross-functional team to look into “a range of potential outcomes” and nail down strategies to help mitigate the potential impact of future trade and tariff policies.That includes managing current inventory levels in “certain jurisdictions,” leveraging its domestic manufacturing footprint and the potential production of active pharmaceutical ingredients and products in the U.S., according to Denton. 

iStock, Jolygon Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis while all three companies are fighting for new patients. A three-way tussle has emerged in the growing ATTR amyloidosis market as Alnylam and BridgeBio Pharma have secured FDA approvals to challenge Pfizer. Tafamidis, which Pfizer sells as Vyndaqel, Vyndamax and Vynmac, had the ATTR amyloidosis with cardiomyopathy (ATTR-CM) market to itself for five years. But BridgeBio won approval for Attruby, a drug with the same mechanism of action as tafamidis, in November 2024. Then the oral transthyretin stabilizers were joined on the market by the first silencer, Alnylam’s Amvuttra, in March. Amvuttra was already approved in ATTR with polyneuropathy (ATTR-PN). ATTR-CM causes stiffening of cardiac muscle and heart failure, leading to death in around 2.5 years if left untreated. Cardiac capacity cannot be regained once lost. BridgeBio estimates there are around 240,000 ATTR-CM patients in the U.S. and BMO Capital Markets analyst Kostas Biliouris said he believes the market is big enough to accommodate multiple assets. Even so, competition is inevitable and the stakes are high. Pfizer Bullish as Rivals Arrive Pfizer reported $5.4 billion in sales for tafamidis in 2024, up more than 60% year on year. Matt Outten, chief commercial officer at BridgeBio, said at a Leerink investor event in March that around 24,000 people are on tafamidis. And about 30% to 40% of patients on tafamidis “are probably progressing” while a further 2,000 to 3,000 people are being newly diagnosed each quarter, he added. Alnylam and BridgeBio are now competing for people who are switching from tafamidis. Pfizer CFO David Denton acknowledged the effect of the new entrants on a call with analysts to discuss 2025 guidance, saying that “Vyndaqel’s growth will be tempered primarily due to the unfavorable impact of the IRA and new competition in the U.S.” Pfizer CEO Albert Bourla provided a detailed look at how the company expects the market to evolve at a TD Cowen event in March. The chief executive is confident Pfizer can keep current users, arguing that physicians “will never switch a patient to something different” when a medicine is working well. He is equally bullish on the company’s ability to compete for first-line users. Bourla said that Pfizer “will maintain a lion’s market share” for new prescriptions “because of the network, the understanding of physicians of the brand.” Asked if he expects Pfizer to dominate new prescriptions, Bourla said “correct,” adding that the company will be “super dominant on the current prescriptions.” Alnylam Targets First-Line Market Alnylam has other ideas. On a conference call with analysts to discuss the FDA approval, Alnylam CEO Yvonne Greenstreet said Amvuttra has the potential to become the new standard of care. Tolga Tanguler, chief commercial officer at the company, used the call to make the case that ATTR-CM patients, knowing cardiac function cannot be regained, will want to get the injectable Amvuttra as a first-line therapy. The biotech is forecasting sales of Amvuttra and Onpattro, the company’s other approved ATTR-PN drug, will rise to between $1.6 billion and $1.725 billion this year, a 36% increase at the midpoint of the range. Last year, when Alnylam only had approvals in ATTR-PN, the franchise grew 34%. Alnylam is charging a premium for Amvuttra. The annual wholesale acquisition cost for Pfizer’s tafamidis is $268,000 . BridgeBio priced Attruby at $244,500 a year. Alnylam set Amvuttra’s list price at an annual cost of $476,000. Tanguler said Alnylam will cut the net price of Amvuttra “via rebates and value-based agreements” as prescription uptake increases. The Inflation Reduction Act could also impact what patients pay for Amvuttra. The law capped Medicare Part D out-of-pocket spending at $2,000. A patient who has already hit the cap, because they are on other medications, will pay nothing to take tafamidis or Attruby. Amvuttra is a Medicare Part B drug. These services have a 20% coinsurance. Medicare Advantage caps the annual cost at $9,350. Amvuttra has confirmed coverage for virtually all insured ATTR-PN patients, Tanguler said, and Alnylam expects similarly broad coverage in ATTR-CM. The biotech is talking to U.S. payers and expects ATTR-CM sales to start ramping up in the second half of 2025. Alnylam is taking other steps to ensure patients can access Amvuttra, with a focus on the 170 health systems where 80% of ATTR-CM patients are treated. Alnylam has been optimizing access pathways at those health systems to ensure people can receive the drug “at a convenient location, whether that’s an office, at an infusion center or, in some cases, in the patient’s home,” Tanguler said. The biotech had nearly 2,000 alternate sites of care as of March 20, Tanguler said, and was close to its goal of establishing treatment sites within 10 miles of 90% of patients. BridgeBio Builds Launch Momentum Alnylam is presenting Amvuttra’s quarterly subcutaneous dosing as a strength. BridgeBio pushed back against that idea. Outten said some ATTR-CM patients cannot drive or prefer not to. Family members might need to take hours out of their days to drive patients, who are often seniors, for injections, Outten said. While Alnylam’s roll out of alternate sites of care could bring down geographic barriers to Amvuttra use, Outten expects some patients to prefer oral treatments. ATTR-CM patients already take pills multiple times a day for conditions such as high blood pressure, Outten said, so adding another drug has little effect on their routines. Data on BridgeBio’s Attruby launch predate the approval of Amvuttra. The first two months of the launch exceeded expectations , BMO’s Biliouris said, with around 500 HCPs writing prescriptions for more than 1,000 patients. Biliouris predicted BridgeBio will generate first-quarter sales of $7 million to $14 million, beating the $5 million to $6 million consensus analyst forecast. The competitive landscape looks likely to change in the coming years. Pfizer’s tafamidis is set to lose patent protection in the U.S. in 2028, allowing cheaper generic copies to come to market. Tanguler said the availability of generics might make combination therapy viable. In an April 4 note to investors, Mizuho analysts said that Pfizer’s work on a tafamidis tablet, which is in Phase I , could result in a formulation with patent protection through 2043. The Mizuho team cited Pfizer’s investment in the tablet formulation as evidence the ATTR-CM market “is likely to be more durable beyond 2028.” With Alnylam, BridgeBio and Pfizer all betting on the opportunity, and generic companies waiting in the wings, the stage is set for intense competition and blockbuster sales.